Xanthones

Compound Class	Xanthones — tricyclic dibenzo-γ-pyrone polyphenols; over 60 distinct xanthones identified in mangosteen alone
Representative Members	α-Mangostin (most abundant), γ-mangostin, garcinone E, gartanin
Botanical Sources	Garcinia mangostana (mangosteen)
Plant Part(s)	Pericarp (fruit rind) — not the edible white aril
Typical Standardisation	Total xanthones or α-mangostin by HPLC; 10–40% common for standardized extract, up to 90% for isolated α-mangostin
Primary Applications	Anti-inflammatory and antioxidant formulation, immune-modulatory positioning, topical/cosmetic actives
Claim Strength (Overview)	Emerging — extensive mechanistic and preclinical data, but human clinical trial evidence remains limited
Buy from Herbuno	Xanthones 40% Powder (Mangosteen Extract) | Standardized Garcinia mangostana → Alpha-Mangostin 90% Powder (Mangosteen) | High-Purity Isolate | Garcinia mangostana →

Name origin: Xanthone derives from the Greek xanthos (yellow), reflecting the characteristic yellow pigmentation of the compound class; the mangosteen-specific members take their names from the fruit itself, with α- and γ-mangostin distinguished by the Greek-letter convention indicating the order in which they were isolated and characterized. Traditional use: Mangosteen, native to Southeast Asia and long dubbed the "queen of fruits," has a documented traditional-medicine history across Thailand, Malaysia, Indonesia, and the Philippines in which the pericarp (the thick, bitter purple rind — not the sweet white flesh that is eaten) was decocted and used for diarrhoea, dysentery, skin infections, and wound care, a distinction that remains commercially significant since the xanthone content is concentrated almost entirely in the discarded rind. Research trajectory: Mangosteen xanthones entered Western commercial awareness through a wave of "superfruit" juice marketing in the early 2000s, which considerably outpaced the underlying clinical evidence; the subsequent scientific literature has been substantial but heavily weighted toward in-vitro and animal mechanistic work, with human randomized controlled trial data remaining comparatively sparse relative to the volume of preclinical publication and commercial claim-making. Commercial source: Mangosteen pericarp extract standardized to total xanthone or specifically to α-mangostin content by HPLC is the commercial format, with the raw material being a genuine agricultural by-product stream of the fresh-fruit trade.

---

Evidence for Xanthones Applications

The mechanistic case for mangosteen xanthones is well developed. A comprehensive review consolidating the literature on α-mangostin found consistent anti-inflammatory activity operating through suppression of pro-inflammatory cytokines, modulation of immune cell activity, and inhibition of the NF-κB and MAPK signalling pathways, alongside immunomodulatory effects on macrophage polarization, T-cell differentiation, and cytokine production, with efficacy observed across numerous disease models including joint, digestive, metabolic, hepatic, neurological, and respiratory conditions (Biomolecules 2025). Critically, that same review explicitly concludes that α-mangostin’s therapeutic potential warrants further investigation through preclinical and clinical studies to validate efficacy and safety — an author-stated acknowledgement that human validation is still outstanding. Claim strength: Emerging.

Cellular-level work has characterized the mechanism in metabolically relevant tissue: α- and γ-mangostin attenuated LPS-induced expression of inflammatory genes including TNF-α, IL-6, and IP-10 in a dose-dependent manner in human macrophages, and attenuated activation of MAPK and AP-1, with γ-mangostin (but notably not α-mangostin) additionally reducing NF-κB; the same study found that pretreating macrophages with γ-mangostin attenuated their ability to induce inflammation and insulin resistance in human adipocytes (Bumrungpert 2010). The differential activity between α- and γ-mangostin on NF-κB is a meaningful formulation detail: an extract standardized solely to α-mangostin may not fully reproduce the activity profile of a broader total-xanthone extract. Claim strength: Emerging.

An important and often-omitted counterpoint deserves explicit mention: a study evaluating dietary α-mangostin in a murine model of experimental colitis found that it exacerbated the pathology, with greater colonic inflammation, greater immune-cell infiltration, and promotion of gut dysbiosis in mice fed the compound — a result directly at odds with the compound’s in-vitro anti-inflammatory profile. This finding underscores that in-vitro anti-inflammatory activity does not reliably predict in-vivo outcomes in the gut, and formulators should avoid inflammatory-bowel-specific claims for this ingredient. Claim strength: Emerging (with contradictory in-vivo signal).

Bioavailability is a substantial and under-discussed constraint for this compound class: α-mangostin is highly lipophilic and poorly water-soluble, with limited oral bioavailability and rapid metabolism, meaning the micromolar concentrations at which anti-inflammatory activity is demonstrated in cell culture are unlikely to be achieved systemically through ordinary oral dosing. This gap between in-vitro potency and achievable plasma exposure is a primary reason the class’s claim strength is rated Emerging rather than Moderate despite the volume of mechanistic literature. Claim strength: Emerging.

Topical and cosmetic applications may be the most defensible near-term use case for mangosteen xanthones, since local application bypasses the oral bioavailability constraint entirely and delivers the compound directly to the target tissue at concentrations closer to those demonstrated active in vitro; the antimicrobial and anti-inflammatory activity documented for α-mangostin against skin-relevant organisms supports this positioning, though formal clinical dermatological trial data remains limited. Claim strength: Emerging.

---

Dosage & Formulator Specification

Herbuno carries mangosteen pericarp extract standardized to 40% and 10% total xanthones by HPLC, alongside isolated α-mangostin at 90% purity for research and high-potency applications, and whole mangosteen extract in powder, water-soluble, and oil-soluble formats for cosmetic and food/beverage formulation. Buyers should note that oil-soluble and lipid-carrier formats are mechanistically well matched to this compound class given α-mangostin’s strong lipophilicity.

Because human clinical dosing data for isolated mangosteen xanthones is limited, dosing guidance for this ingredient rests on a thinner evidentiary footing than for most compounds in this index. Commercial supplement products have commonly used mangosteen extract in the range of several hundred milligrams per day, but there is no well-established dose-response relationship validated in human trials, and formulators should be candid about this rather than implying that a specific serving size is clinically validated.

Analytical verification should specify whether the stated percentage refers to total xanthones or to α-mangostin specifically, as these are different figures from the same material, and ideally should include the α- to γ-mangostin ratio given the documented mechanistic differences between the two (notably that γ-mangostin, not α-mangostin, was the one reducing NF-κB in the human macrophage work cited above). Solvent-residue testing is standard given that xanthone extraction typically uses ethanol or ethyl acetate.

Mangosteen extract is generally well tolerated in commercial use, though the compound class’s poor oral bioavailability means systemic exposure at typical doses is modest. Two formulator cautions warrant explicit mention: first, the murine colitis finding noted above means inflammatory-bowel-condition claims should be avoided; second, some reviews have raised the possibility of interaction with drug-metabolizing pathways, meaning standard caution language regarding concurrent prescription medication use is appropriate pending clearer human pharmacokinetic data.

---

Frequently Asked Questions — Xanthones

Which part of the mangosteen fruit contains the xanthones?
The pericarp — the thick, bitter purple rind — not the sweet white flesh that is normally eaten. This is commercially significant: the xanthone-bearing raw material is essentially a by-product stream of the fresh-fruit trade, and traditional Southeast Asian medicine likewise used the rind rather than the flesh.

How strong is the human evidence for mangosteen xanthones?
Considerably weaker than the volume of published mechanistic research would suggest. The in-vitro and animal literature on anti-inflammatory activity is extensive and consistent, but human randomized controlled trial data remains limited, and review authors themselves explicitly call for clinical validation. Claims should be scoped as Emerging.

Is alpha-mangostin the same as total xanthones?
No. Alpha-mangostin is the single most abundant xanthone in mangosteen, but the pericarp contains over 60 distinct xanthones. A "total xanthones 40%" extract and an "alpha-mangostin 90%" isolate are materially different products, and research suggests gamma-mangostin has some mechanistic activity that alpha-mangostin lacks.

Does mangosteen xanthone absorb well when taken orally?
Not particularly. Alpha-mangostin is highly lipophilic and poorly water-soluble, with limited oral bioavailability and rapid metabolism. The concentrations at which it shows anti-inflammatory activity in cell culture are unlikely to be reached in blood through ordinary oral dosing, which is a key limitation on the ingredient's systemic claims.

Related compounds: Resveratrol, Quercetin, Curcumin, Polyphenols

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery